Clinical Issues in Rheumatoid ArthritisDiscussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Additional Abstracts From the 2017 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting.
November 2017; San Diego, California.
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.
Anderson J, et al. Arthritis Care Res (Hoboken). 2012;64(5):640-647.
Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration.
Bianchi G, et al. Adv Ther. 2016;33(3):369-378
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Cohen SB, et al. Ann Rheum Dis. 2017;76(7):1253-1262.
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Dougados M, et al. Ann Rheum Dis. 2017;76(1):88-95.
Long term safety of filgotinib in the treatment of rheumatoid arthritis: week 84 data from a phase 2b open-label extension study.
Genovese MC, et al. Arthritis Rheumatol. 2017;69 (suppl 10). Abstract 1909.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, et al. Lancet. 2017;390(10093):457-468.
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Fleischmann R, et al. Clin Rheumatol. 2017;36(1):15-24.
Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies.
Fleischmann R, et al. RMD Open. 2017;3(2):e000491.
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.
Genovese MC, et al. Rheumatology. 2018;57(5):900-908.
Upadacitinib (ABT-494) in patients with active rheumatoid arthritis and inadequate response or intolerance to biological DMARDs: a phase 3 randomized, placebo-controlled, double-blind study of a selective JAK-1 inhibitor.
Genovese MC, et al. Arthritis Rheumatol. 2017;69(suppl 10). Abstract 10L.
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Kavanaugh A, et al. Ann Rheum Dis. 2017;76(6):1009-1019.
No effect of baseline serum CRP levels on clinical efficacy parameters in rheumatoid arthritis patients treated with filgotinib: post hoc analysis from two phase 2B studies.
Kavanaugh A, et al. Arthritis Rheumatol. 2017;69 (suppl 10) Abstract 537.
Time to achieve moderate/low disease activity and remission in RA patients on baricitinib compared to adalimumab, methotrexate, and placebo.
Keystone EC, et al. Arthritis Rheumatol. 2017;69 (suppl 10). Abstract 513.
Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate.
Kivitz AJ, et al. Arthritis Rheumatol. 2017;69(4):709-719.
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.
Cycling versus swapping in patients with rheumatoid arthritis with an inadequate response to at least one tumor necrosis factor alpha inhibitor: a systematic review and meta-analysis of observational study.
Lopez-Olivo MA, et al. Arthritis Rheumatol. 2017;69(suppl 10):Abstract 2483.
McInnes IB, Schett G. Lancet. 2017;389(10086):2328-2337.
Scott IC, et al. Drug Saf. 2018 Mar 2. [Epub ahead of print].
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Westhovens R, et al. Ann Rheum Dis. 2017;76(6):998-1008.
Using Imaging to Improve Patient Outcomes
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Discussions and Debates About Moderate-to-Severe Disease
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes